Conditions: Chronic Obstructive Pulmonary Disease
Keywords: COPD
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 55
Healthy volunteers: no

Brief summary:
The primary aim of this study is to investigate the effects of AZD1236 compared with placebo ("inactive substance") in COPD patients by analysing biomarkers for inflammation and tissue degradation in blood, urine and sputum.

Detailed description:

Arms:
arm 1: oral tablet, 75 mg, twice daily during 6 weeks arm 2: Dosing to match AZD1236

Interventions: intervention 1: AZD1236 intervention 2: Placebo
Intervention descriptions: intervention 1: oral tablet, 75 mg, twice daily during 6 weeks intervention 2: Dosing to match AZD1236

Protocol document: